The German startup is the first preclinical biotech company purposely developing small molecule activators of the FOXO3 transcription factor for the treatment of age-related diseases.
Refoxy Pharmaceuticals has raised €9.1M across 1 funding round from 4 investors, most recently a Seed round in Dec 2024. Based in Berlin, Germany; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-12-04 | Seed | €9.1M |
| Apollo Health Ventures,Boehringer Ingelheim Venture Fund (BIVF),High-Tech Gründerfonds (HTGF),NRW Venture |
| View deal → |
